-
Full Steam Ahead: uniQure’s On Track With Hope for Accelerated Approval of Huntington’s Disease Drug
Latest News
-
Huntingtin takes a trip: harmful proteins pass between brain cells
Harmful misfolded huntingtin can travel between brain cells via messenger particles called exosomes
-
Important drug targets yielded by new genetic study of HD
A genetic study confirms that minute differences in DNA repair genes can influence the age of HD symptom onset.
-
Thinking clearly about the earliest symptoms of HD and which brain regions control them
HD reaches more brain structures than we thought: new research broadens our understanding of the earliest signs of HD
-
How NOT to write a news article about a clinical trial
A confusing story about a huntingtin lowering trial is published in the Telegraph, but cool new stuff is happening!
-
Huntington's Disease Therapeutics Conference 2016 – day 3
Stem cells and modeling Huntington's disease in our final Therapeutics Conference report
-
Huntington's Disease Therapeutics Conference 2016 – day 2
Strategies for getting rid of mutant huntingtin & clinical trial updates: day 2 of the HD therapeutics conference
-
Huntington's Disease Therapeutics Conference 2016 – day 1
Proteins and DNA – Jeff and Ed report from day 1 of the 2016 #huntingtonsdisease therapeutics conference
-
Harnessing the power of viruses to treat Huntington's disease
Researchers design a virus to more effectively deliver gene-silencing drugs throughout the brain.
-
Through a Broader Lens: Looking at Non-Motor Symptoms in HD
Sleep deficits precede motor problems in HD
-
Looking Past the Spin: Results from a Clinical Trial of Cysteamine
Phase 2/3 clinical trial results prove inconclusive for Huntington's drug cysteamine.